Trial Profile
Phase I/II study to evaluate the safety and efficacy of intrathecal injection of KP-100IT in subjects with acute spinal cord injury
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Dec 2022
Price :
$35
*
At a glance
- Drugs Oremepermin alfa (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kringle Pharma
- 20 Jul 2020 According to a Kringle Pharma media release, data from this study were published in the Journal of Neurotrauma (22 May 2020 online).
- 02 Mar 2020 According to a Kringle Pharma media release, KP-100IT was designated as an orphan drug in Japan on the basis of the data from this trial.
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.